The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacodynamic effects (gastric emptying),
safety, tolerability, and pharmacokinetics of single doses of GSK962040 in Type 1 diabetic
patients with gastroparesis.